Notably, platelet-specific deletion of lrrc32 interferes intratumoral TGF-β activity and enhances anti-tumor immunity in melanoma and colon cancer models [79], and pharmacologic inhibition of platelet activation or TGF-β maturation further boosts chimeric antigen receptor T-cell (CAR-T) therapy and ICIs in preclinical studies [12, 79]. Here, TGFB1 is linked to neoplasm.